$SRPT News

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to Decline

Leadership changes afoot at two CGT biotechs

Morgan Stanley Views Sarepta CEO Transition As A ‘Positive’ – So, Why Is It Cautious On SRPT Stock In The Near Term?

Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug Ingram

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space

Following FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued?

The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies

Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs

Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027

Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript

A Look At Sarepta Therapeutics (SRPT) Valuation After Q1 Profitability Return And Pipeline Progress

Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says

Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?

Sarepta tumbles as its gene therapy sales decline further